Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Celgene Corporation



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.9%. By the end of trading, Celgene Corporation fell $1.91 (-1.2%) to $161.52 on light volume. Throughout the day, 1,971,599 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2,880,800 shares. The stock ranged in price between $160.71-$163.95 after having opened the day at $163.72 as compared to the previous trading day's close of $163.43. Other companies within the Drugs industry that declined today were:

Mast Therapeutics



), down 39.4%,

Echo Therapeutics



), down 15.5%,

Heat Biologics



TheStreet Recommends

), down 8.6% and

Amarin Corporation



), down 6.2%.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $67.6 billion and is part of the health care sector. The company has a P/E ratio of 47.1, above the S&P 500 P/E ratio of 17.7. Shares are up 109.0% year to date as of the close of trading on Tuesday. Currently there are 20 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Celgene Corporation

as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front,

Oxygen Biotherapeutics



), up 20.6%,




), up 17.3%,

Prosensa Holding N.V



), up 15.5% and

Oncolytics Biotech



), up 11.3% , were all gainers within the drugs industry with

Questcor Pharmaceuticals



) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.